Browse by author
Lookup NU author(s): Professor Stephen O'Brien
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
In the multinational IRIS study comparing imatinib with interferon plus cytarabine (IFN/Ara-C) in patients with newly diagnosed chronic-phase chronic myelogenous leukemia (CP CML), imatinib demonstrated significantly higher rates of complete cytogenetic responses (CCyRs) and improved progression-free survival (PFS). However, because of a high early crossover rate to imatinib, survival benefit was not assessable. Here, we report the result of a study comparing long-term outcome of patients included in 2 prospective randomized trials: 551 patients assigned to imatinib in the IRIS trial from 2000 to 2001 and 325 patients who received the combination IFN/Ara-C in the CML91 trial between 1991 and 1996 before imatinib was available. With a follow-up of 42 months for both groups of patients, estimated CCyR, survival free of transformation, and overall survival were significantly higher with imatinib compared with IFN/Ara-C (P < .001, P = .004, and P < .001, respectively). Improved overall survival was also confirmed within different Sokal prognostic risk groups. Of interest, among all patients who achieved major cytogenetic response or CCyR at 12 months, the survival rate was similar irrespective of their treatment. In conclusion, within the limitation of this historical comparison, there is a survival advantage from first-line therapy with imatinib over IFN/Ara-C.
Author(s): Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA, O'Brien SG, So C, Massimini G, Guilhot F
Publication type: Article
Publication status: Published
Journal: Blood
Year: 2006
Volume: 108
Issue: 5
Pages: 1478-1484
ISSN (print): 0006-4971
ISSN (electronic): 1528-0020
URL: http://dx.doi.org/10.1182/blood-2006-02-001495
DOI: 10.1182/blood-2006-02-001495
Altmetrics provided by Altmetric
